Barclays lowered the firm’s price target on Exelixis to $24 from $25 and keeps an Overweight rating on the shares. The analyst says Q2 Cabozantinib sales beat consensus.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EXEL: